LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 diseaseFDA designations underscore ...
The company has also received orphan drug, rare pediatric disease, and fast-track designations for LTS-101 as a potential treatment for the fatal neurodegenerative disease.
Latus Bio Inc. has reported IND clearance by the FDA for LTS-101, a gene therapy candidate to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease. The ...
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...
The National Institutes of Health awarded more than $8 million to the Kennedy Krieger Institute for researching rare disorders that negatively affect children. The money will establish a "first-of-its ...
Hosted on MSN
Scientists edge closer to beating world's deadliest disease with first vaccine in 100 years
Scientists may be on the cusp of developing a new vaccine to combat tuberculosis (TB), one of the world's deadliest diseases. TB takes more than 1million lives each year and is particularly deadly in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback